270 related articles for article (PubMed ID: 36866391)
1. Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice.
Seedorf K; Weber C; Vinson C; Berger S; Vuillard LM; Kiss A; Creusot S; Broux O; Geant A; Ilic C; Lemaitre K; Richard J; Hammoutene A; Mahieux J; Martiny V; Durand D; Melchiore F; Nyerges M; Paradis V; Provost N; Duvivier V; Delerive P
JHEP Rep; 2023 Apr; 5(4):100651. PubMed ID: 36866391
[TBL] [Abstract][Full Text] [Related]
2. A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease.
Hammoutene A; Laouirem S; Albuquerque M; Colnot N; Brzustowski A; Valla D; Provost N; Delerive P; Paradis V;
JHEP Rep; 2023 Oct; 5(10):100845. PubMed ID: 37663119
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
Shimozono R; Asaoka Y; Yoshizawa Y; Aoki T; Noda H; Yamada M; Kaino M; Mochizuki H
Mol Pharmacol; 2013 Jul; 84(1):62-70. PubMed ID: 23592516
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.
Lee DH; Han DH; Nam KT; Park JS; Kim SH; Lee M; Kim G; Min BS; Cha BS; Lee YS; Sung SH; Jeong H; Ji HW; Lee MJ; Lee JS; Lee HY; Chun Y; Kim J; Komatsu M; Lee YH; Bae SH
Free Radic Biol Med; 2016 Oct; 99():520-532. PubMed ID: 27634173
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis.
Okada K; Warabi E; Sugimoto H; Horie M; Tokushige K; Ueda T; Harada N; Taguchi K; Hashimoto E; Itoh K; Ishii T; Utsunomiya H; Yamamoto M; Shoda J
J Gastroenterol; 2012 Aug; 47(8):924-35. PubMed ID: 22367278
[TBL] [Abstract][Full Text] [Related]
7. Physalin B ameliorates nonalcoholic steatohepatitis by stimulating autophagy and NRF2 activation mediated improvement in oxidative stress.
Zhang MH; Li J; Zhu XY; Zhang YQ; Ye ST; Leng YR; Yang T; Zhang H; Kong LY
Free Radic Biol Med; 2021 Feb; 164():1-12. PubMed ID: 33388433
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2.
Bathish B; Robertson H; Dillon JF; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2022 Aug; 188():221-261. PubMed ID: 35728768
[TBL] [Abstract][Full Text] [Related]
9. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
10. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
[TBL] [Abstract][Full Text] [Related]
11. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
12. Nomilin and its analogue obacunone alleviate NASH and hepatic fibrosis in mice via enhancing antioxidant and anti-inflammation capacity.
Han Y; Luo L; Li H; Zhang L; Yan Y; Fang M; Yu J; Gao X; Liu Y; Huang C; Fan S
Biofactors; 2023; 49(6):1189-1204. PubMed ID: 37401768
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of NRF2 is correlated with the magnitude of inflammation and fibrosis in chronic liver disease.
To K; Okada K; Watahiki T; Suzuki H; Tsuchiya K; Tokushige K; Yamamoto M; Ariizumi SI; Shoda J
Cancer Med; 2023 Oct; 12(19):19423-19437. PubMed ID: 37732511
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development.
Ramadori P; Drescher H; Erschfeld S; Schumacher F; Berger C; Fragoulis A; Schenkel J; Kensler TW; Wruck CJ; Trautwein C; Kroy DC; Streetz KL
Free Radic Biol Med; 2016 Feb; 91():114-26. PubMed ID: 26698665
[TBL] [Abstract][Full Text] [Related]
15. Placental extract ameliorates liver fibrosis in a methionine- and choline-deficient diet-induced mouse model of non-alcoholic steatohepatitis.
Yamauchi A; Tone T; Toledo A; Igarashi K; Sugimoto K; Miyai H; Deng D; Nakamura J; Lim HS; Kaku T; Hirano E; Shindo T
Biomed Res; 2020; 41(1):1-12. PubMed ID: 32092735
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.
Alshawsh MA; Alsalahi A; Alshehade SA; Saghir SAM; Ahmeda AF; Al Zarzour RH; Mahmoud AM
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164140
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis.
Yang JJ; Tao H; Hu W; Liu LP; Shi KH; Deng ZY; Li J
Cell Signal; 2014 Nov; 26(11):2381-9. PubMed ID: 25049078
[TBL] [Abstract][Full Text] [Related]
18. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
[TBL] [Abstract][Full Text] [Related]
20. Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH.
Fernández-Ginés R; Encinar JA; Escoll M; Carnicero-Senabre D; Jiménez-Villegas J; García-Yagüe ÁJ; González-Rodríguez Á; Garcia-Martinez I; Valverde ÁM; Rojo AI; Cuadrado A
Redox Biol; 2024 Feb; 69():103027. PubMed ID: 38184999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
